ライフサイエンスコーパス: diabetic macular edema

1 postoperative macular edema in patients with diabetic macular edema.

2 d vascular leakage observed in patients with diabetic macular edema.

3 either proliferative diabetic retinopathy or diabetic macular edema.

4 e nonsurgical management options in treating diabetic macular edema.

5 er-reviewed literature regarding therapy for diabetic macular edema.

6 al therapeutic approach for the treatment of diabetic macular edema.

7 mproving visual acuity in some patients with diabetic macular edema.

8 ical trials for the treatment of uveitis and diabetic macular edema.

9 otentially abate or restore vision loss from diabetic macular edema.

10 rs a protective effect on the development of diabetic macular edema.

11 of optical coherence tomography detection of diabetic macular edema.

12 diabetic retinopathy (DR) in the absence of diabetic macular edema.

13 vascular age-related macular degeneration or diabetic macular edema.

14 ates with increased vascular permeability in diabetic macular edema.

15 vascular age-related macular degeneration or diabetic macular edema.

16 such as age-related macular degeneration or diabetic macular edema.

17 lar degeneration, retinal vein occlusion and diabetic macular edema.

18 ) and other factors is an important cause of diabetic macular edema.

19 lying capillary nonperfusion in eyes without diabetic macular edema.

20 dothelial growth factor for the treatment of diabetic macular edema.

21 se in diabetic retinopathy in the absence of diabetic macular edema.

22 injections during 6 months in patients with diabetic macular edema.

23 (3-fold) and serum samples of patients with diabetic macular edema (1.6-fold) measured by Western bl

24 Of 124 eyes analyzed, 60 (48.4%) had diabetic macular edema, 32 (25.8%) had neovascular age-r

25 ge-related macular degeneration (12.9%), and diabetic macular edema (5.6%).

26 omenon of temporary paradoxical worsening of diabetic macular edema after insulin treatment has been

27 eakage from the retinal vasculature leads to diabetic macular edema, an important cause of vision los

28 of randomized trial data on 660 adults with diabetic macular edema and decreased VA (Snellen equival

29 and bevacizumab may blunt the progression of diabetic macular edema and diabetic retinopathy.

30 Pars plana vitrectomy for diabetic macular edema and for traction retinal detachme

31 s (of 486 participants) with center-involved diabetic macular edema and no preexisting open-angle gla

32 In eyes with center-involved diabetic macular edema and no prior open-angle glaucoma,

33 re nonproliferative diabetic retinopathy and diabetic macular edema and of a normal nondiabetic eye w

34 e understanding, diagnosis, and treatment of diabetic macular edema and other ocular diseases with ou

35 f endothelial dysfunction, which can lead to diabetic macular edema and proliferative diabetic retino

36 ed retinal vascular leakage in patients with diabetic macular edema and reduced the rate of sustained

37 iseases associated with BRB leakage, such as diabetic macular edema and retinopathy.

38 nosed as having diabetic retinopathy without diabetic macular edema and underwent fluorescein angiogr

39 treal Aflibercept Injection in Patients With Diabetic Macular Edema) and VIVID (Intravitreal Afliberc

40 treal Aflibercept Injection in Patients With Diabetic Macular Edema) and VIVID (Intravitreal Afliberc

41 nts with retinal disease, including uveitis, diabetic macular edema, and age-related macular degenera

42 raded 3 to 7 times for diabetic retinopathy, diabetic macular edema, and image gradability by a panel

43 ular age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion.

44 ase C (PKC) inhibitors for the management of diabetic macular edema are underway.

45 cizumab, and ranibizumab in the treatment of diabetic macular edema are unknown.

46 improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended

47 In a subset of patients, diffuse diabetic macular edema can result from a taut and conden

48 Diabetic macular edema causes impairment of vision in pa

49 n included age-related macular degeneration, diabetic macular edema, central and branch retinal vein

50 ized the treatment of clinically significant diabetic macular edema (CSDME); yet these agents are exp

51 who had at least 1 eye with central-involved diabetic macular edema, defined as Stratus central subfi

52 R without macular edema (PDR) (10 eyes), and diabetic macular edema (DME) (14 eyes).

53 gns of retinopathy (n = 9) and patients with diabetic macular edema (DME) (n = 31) were compared with

54 7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its

55 The prevalence of persistent diabetic macular edema (DME) after months of anti-vascul

56 10 eyes of healthy subjects, 10 eyes with diabetic macular edema (DME) and 10 eyes with neovascula

57 Patients with diabetic macular edema (DME) are at high risk of vascula

58 cation and characterization of patients with diabetic macular edema (DME) are important for individua

59 mpairing (VA 20/32 or worse) center-involved diabetic macular edema (DME) at baseline were required t

60 average, a shorter duration of diabetes and diabetic macular edema (DME) at baseline, were less like

61 brovascular accidents (CVA) in patients with diabetic macular edema (DME) compared with diabetic pati

62 travitreal aflibercept injections (IAIs) for diabetic macular edema (DME) during the phase III VISTA

63 helial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic

64 Diagnosing diabetic macular edema (DME) from monocular fundus photo

65 ), and ranibizumab (0.3 mg) for treatment of diabetic macular edema (DME) involving the center of the

66 Diabetic macular edema (DME) is a leading cause of visio

67 ntravitreal dexamethasone implant therapy in diabetic macular edema (DME) is associated with long-ter

68 Treatment for diabetic macular edema (DME) is continuously evolving.

69 Diabetic macular edema (DME) is the major cause of visio

70 Diabetic macular edema (DME) is the most common cause of

71 flibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME) might influence interpretat

72 In contrast, diabetic macular edema (DME) morphology-related measures

73 The potential effect of treatments for diabetic macular edema (DME) on driving should be of val

74 d aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after i

75 tereoscopic fundus photographs, we evaluated diabetic macular edema (DME) progression and DR progress

76 itial monthly dosing period) (2q8) and other diabetic macular edema (DME) therapies at doses licensed

77 ser, and sham in the first-line treatment of diabetic macular edema (DME) to inform technology assess

78 pathy severity score (DRSS) in patients with diabetic macular edema (DME) treated with intravitreal r

79 factor (VEGF) medicines have revolutionized diabetic macular edema (DME) treatment.

80 Patients with diabetic macular edema (DME) who received sham control o

81 (PDR) without macular edema, and 27 eyes had diabetic macular edema (DME) with either NPDR or PDR.

82 Diabetic macular edema (DME) with neurosensory retinal d

83 t-effectiveness analysis of the treatment of diabetic macular edema (DME) with ranibizumab plus promp

84 and functional characteristics in eyes with diabetic macular edema (DME) with subfoveal neuroretinal

85 dothelial growth factor therapy in eyes with diabetic macular edema (DME) with vision loss after macu

86 dothelial growth factor therapy in eyes with diabetic macular edema (DME) with vision loss after macu

87 ure visual acuity (VA) in eyes with baseline diabetic macular edema (DME) would substantively improve

88 nonproliferative DR (NPDR), 51 with NPDR and diabetic macular edema (DME), and 18 with proliferative

89 Retinal hypoxia also contributes to diabetic macular edema (DME), and because of the absence

90 ular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion

91 ular age-related macular degeneration (AMD), diabetic macular edema (DME), central and branch retinal

92 Thickening of the center of the retina, diabetic macular edema (DME), is the most common cause o

93 useful therapeutic target for patients with diabetic macular edema (DME), perhaps in combination wit

94 lar age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion, ch

95 with DR of varying severity, with or without diabetic macular edema (DME), using en face Doppler OCT.

96 Diabetic retinopathy, diabetic macular edema (DME), vision-threatening diabeti

97 Total of 456 patients with center-involved diabetic macular edema (DME).

98 vision-related function after treatment for diabetic macular edema (DME).

99 al macular thickness (CMT) in a patient with diabetic macular edema (DME).

100 e treatment of diabetic retinopathy (DR) and diabetic macular edema (DME).

101 l acuity outcomes in patients suffering from diabetic macular edema (DME).

102 ributes significantly to the pathogenesis of diabetic macular edema (DME).

103 asurements in subjects with center-involving diabetic macular edema (DME).

104 proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).

105 se of OCT in the diagnosis and management of diabetic macular edema (DME).

106 ula-in the study of diabetic retinopathy and diabetic macular edema (DME).

107 anaging diabetic retinopathy (DR), including diabetic macular edema (DME).

108 laser photocoagulation for center-involving diabetic macular edema (DME).

109 lting in peripheral vision loss or worsening diabetic macular edema (DME).

110 ogical activity of AKB-9778 in patients with diabetic macular edema (DME).

111 (PDR), with or without concomitant baseline diabetic macular edema (DME).

112 review and meta-analysis of dyslipidemia and diabetic macular edema (DME).

113 yes with current or resolved center-involved diabetic macular edema (DME).

114 and recent changes in treatment paradigm for diabetic macular edema (DME).

115 t age-related macular degeneration (AMD) and diabetic macular edema (DME).All patients were operated

116 related macular degeneration (AMD, n = 400), diabetic macular edema (DME, n = 400), or retinal vein o

117 ith type 2 diabetes and severe stages of DR (diabetic macular edema [DME] and proliferative diabetic

118 rative DR [NPDR], proliferative DR [PDR], or diabetic macular edema [DME]) or "any DR" (further subcl

119 vascular age-related macular degeneration or diabetic macular edema does not respond to an initial an

120 vascular age-related macular degeneration or diabetic macular edema does not respond to an initial an

121 included 5 pregnant women who presented with diabetic macular edema during pregnancy in the period fr

122 ) grade during the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) A and B Phase III clinical

123 ctiveness of ranibizumab in the treatment of diabetic macular edema has been proven with large clinic

124 acular laser, other treatment modalities for diabetic macular edema have been evaluated.

125 Trials of ranibizumab in diabetic macular edema have demonstrated excellent effic

126 cept for age-related macular degeneration or diabetic macular edema in a 9-member retinal specialty p

127 tently prevents or reverses visual loss from diabetic macular edema in all patients.

128 omated detection of diabetic retinopathy and diabetic macular edema in retinal fundus photographs.

129 ess levels to have reasonable certainty that diabetic macular edema involving the CSF is present usin

130 Diabetic macular edema involving the foveal center that

131 Diabetic macular edema involving the foveal center was o

132 ed 660 adults (mean age, 61+/-10 years) with diabetic macular edema involving the macular center to r

133 Diabetic macular edema is one of the leading causes of v

134 Although the pathophysiology of diabetic macular edema is unknown, various demographic,

135 is of proliferative diabetic retinopathy and diabetic macular edema, leading causes of vision loss in

136 reomacular separation occurring in eyes with diabetic macular edema may facilitate spontaneous resolu

137 s and improve visual acuity in patients with diabetic macular edema (ME).

138 ore, evaluating the effects of therapies for diabetic macular edema on development or worsening of PD

139 ade, and presence of morphologic features of diabetic macular edema on Spectralis optical coherence t

140 or severe diabetic retinopathy as defined by diabetic macular edema or proliferative diabetic retinop

141 A literature search for "diabetic macular edema" or "diabetic maculopathy" was pe

142 te and worse diabetic retinopathy, referable diabetic macular edema, or both, were generated based on

143 Diabetic macular edema patients with VMA have a greater

144 In diabetic macular edema, ranibizumab has shown greater ef

145 Diabetic macular edema represents an important cause of

146 Diabetic macular edema required the greatest number of o

147 Diabetic macular edema, resulting from increased microva

148 tment of various neovascular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroida

149 dothelial growth factor agent ranibizumab in diabetic macular edema, retinal vein occlusion, pseudoph

150 Ranibizumab therapy in the treatment of diabetic macular edema seems to improve retinal function

151 Diabetic macular edema severity was classified as mild,

152 d may become an interesting novel target for diabetic macular edema therapy.

153 The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial

154 ar endothelial growth factor agents to treat diabetic macular edema warrant further assessment.

155 Diabetic macular edema was defined as absent or present

156 Diabetic macular edema was not associated with depressiv

157 ohort (individuals with diabetes but without diabetic macular edema) was enrolled.

158 (MMP-9), which is increased in patients with diabetic macular edema, was capable of cleaving netrin-1

159 CF photographs of 30 eyes (20 patients) with diabetic macular edema were obtained.

160 in optical coherence tomography features of diabetic macular edema were seen with ranibizumab therap

161 Long-term visual outcomes for treatment of diabetic macular edema with ranibizumab are excellent, b

162 ee eyes of 33 patients with center-involving diabetic macular edema, with best corrected visual acuit

163 CT is a useful tool to detect and to measure diabetic macular edema without the need for pupil dilata

164 rated clinical efficacy for the treatment of diabetic macular edema without visible signs of retinal